Oral Carnitine in Heart Failure Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Levocarnitine: Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months.

Study summary

Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.

Eligibility

Primary outcome measure(s)

• Recruitment Rate — From study start to end of study at 52 weeks
  % of eligible patients enrolled over the study period
• Retention Rate — From enrollment to end of treatment at 6 months
  % of enrolled participants completing final follow up
• Intervention adherence — From enrollment to end of study treatment at 6 months
  Medication compliance measured by the % of prescribed L-carnitine doses taken. Pill counts will be completed at the end of the medication intervention time period at Visit 2.
• Safety and Tolerability (adverse events) — From enrollment to end of treatment at 6 months
  Participants will be monitored throughout the study for any adverse events.
• Data Completeness — From start of study to end of study at 52 weeks
  % of participants with complete data for each outcome

Trial sites (1)

More London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials in Canada

Other trials for the same condition